Prothena

Genentech's Phase IIb PADOVA trial on prasinezumab for early-stage Parkinson’s showed potential in delaying motor progression, with notable effects in levodopa users. The drug targets α-synuclein to slow disease progression. Results support further investigation, with ongoing studies and plans for future research directions.

Roche's Phase IIb PADOVA study of prasinezumab, an investigational mAb for early-stage Parkinson’s disease, missed the primary endpoint but showed potential efficacy, particularly in levodopa-treated patients. Prasinezumab was well-tolerated, with no new safety signals. Roche and Prothena aim to develop disease-modifying treatments targeting α-synuclein.

Prasinezumab, an investigational monoclonal antibody, did not achieve statistical significance for the primary endpoint in the Phase IIb PADOVA trial for early-stage Parkinson disease. However, it showed potential efficacy with a numerical delay in motor progression and positive trends across multiple secondary and exploratory endpoints. The drug targets α-syn protein buildup to inhibit PD progression and is under evaluation in ongoing trials.

Roche's experimental Parkinson’s drug, prasinezumab, failed another key trial but shows potential in levodopa users, prompting further exploration. Despite mixed results, Roche plans continued studies and data evaluation.

Roche and Prothena's prasinezumab, targeting alpha-synuclein for Parkinson's, missed primary endpoint in phase 2b PADOVA trial but showed numerical delay in motor progression and positive trends on secondary endpoints. Roche plans further exploration and collaboration with Parkinson's community.

Roche's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson's disease missed its primary endpoint but showed potential clinical benefits, particularly in levodopa-treated patients, with a favorable safety profile.

Prasinezumab showed potential clinical efficacy in delaying motor progression in early-stage Parkinson’s disease, with positive trends in secondary endpoints and no new safety signals. Genentech plans further evaluation and collaboration with health authorities to determine next steps.

Roche partnered with Prothena in 2013 to develop prasinezumab for Parkinson’s disease. The PADOVA Phase IIb trial evaluates prasinezumab's efficacy and safety in 586 early-stage patients, focusing on motor progression. Roche aims to slow Parkinson's progression by targeting underlying disease processes, emphasizing neuroscience research for chronic diseases.

Genentech's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson’s disease missed the primary endpoint but showed potential benefits, especially in levodopa-treated patients. The drug was well-tolerated with no new safety concerns. Further evaluation and collaboration with health authorities are planned to determine next steps.

Genentech's Phase IIb PADOVA study on prasinezumab for early-stage Parkinson's disease missed the primary endpoint but showed potential benefits, including delayed motor progression and positive trends in secondary endpoints. Prasinezumab was well-tolerated with no new safety concerns. Further data evaluation and collaboration with health authorities are planned.